Cabbacis Granted U.S. Patent for Vaporizer Pods Containing Tobacco and Hemp

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on its patented harm-reduction products being developed under the iBlend™ brand name, today announced that the United States Patent and Trademark Office has issued a patent to Cabbacis for vaporizer pods for oral electronic vaporizers.

U.S. Patent No. 12,527,346, which expires on January 1, 2039, includes seven claims on pods for electronic vaporizers. The claims cover vaporizer pods comprising blends of reconstituted tobacco and reconstituted hemp with CBGA being the most abundant cannabinoid. Reconstituted tobacco is typically used in closed-end electronic vaporizer pods. Commercial examples of popular, closed-end electronic vaporizers – also known as heated tobacco products – include IQOS®, Ploom® and glo®.

Vaporizer pods covered under the 346 patent are expected to provide consumers with pleasant and differentiated taste and sensory characteristics, as compared to the above three vaporizer brands that contain tobacco without any hemp.

Hemp became legal nationwide in the United States under the 2018 Farm Bill and is not intoxicating since it contains equal to or less than 0.3% THC. Hemp strains with much less than 0.3% THC, or trace levels, are available for the Company’s products.

Cabbacis owns three other previously-issued U.S. patents covering vaporizer pods containing tobacco and hemp: 10,777,091, 10,973,255 and 12,349,724 along with various international vaporizer pod patents. Cabbacis also owns various U.S. patents covering cigarettes with blends of very-low-nicotine tobacco and hemp, and its products in development are patented in many of the largest tobacco markets across the globe, including the United States, China, Europe, Brazil, Japan and South Korea.

Joseph Pandolfino, Chief Executive Officer of Cabbacis, commented, “We are pleased to announce this new U.S. patent for vaporizer pods, further fortifying our already robust intellectual property position. This patent, when taken in tandem with our existing patents, comprehensively cover, across more than 30 countries, vaporizer pods comprising blends of conventional-nicotine tobacco and hemp or very-low-nicotine tobacco and hemp, and/or very-low-nicotine cigarettes comprising blends of very-low-nicotine tobacco and hemp.”

About Cabbacis

Cabbacis (OTCQB: CABI) is focused on commercializing groundbreaking, patented harm-reduction tobacco products for the world's one billion smokers. Led by its flagship iBlend™ very-low-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBlend™ predominately contains very-low-nicotine tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, transitioning to less harmful tobacco products, and/or increasing quit attempts. The Company also plans to commercialize very-low-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.

In a clinical trial reported by Cabbacis, the Company’s very-low-nicotine cigarettes were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Cabbacis holds a global patent portfolio of 36 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico and Brazil – where approximately two-thirds of the world's smokers collectively reside.

To learn more, please visit cabbacis.com or follow us on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in "Risk Factors" in our Regulation A Offering Circular qualified by the SEC on November 24, 2025 and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.